- Home
- FSEA vs LITS Comparison
FSEA vs LITS Comparison
Compare FSEA & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FSEA | LITS |
|---|---|---|
| Founded | 1890 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 44.4M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | FSEA | LITS |
|---|---|---|
| Price | $16.71 | $1.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 72.4K | ★ 340.3K |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.13 | $0.95 |
| 52 Week High | $16.80 | $3.03 |
Technical Indicators
Market Signals| Indicator | FSEA | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 77.26 | 40.15 |
| Support Level | $16.60 | $0.98 |
| Resistance Level | $16.80 | $1.25 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 55.00 | 0.00 |
Price Performance
Historical ComparisonAbout FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is the savings and loan holding company. The banks business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one- to four-family residential real estate loans, commercial real estate and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. It operates in single segment of Banking Services.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.